Physician profile
Jayesh D Patel
NPI 1548385966
$5,613.31
in general payments reported to CMS, 2019-2025
38 companies · $734 in 2025
The $734 reported for 2025 was more than what 86% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $554 · 2021: $1,201 · 2022: $846 · 2023: $779 · 2024: $606 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,179.47 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $619.31 | 2020-2025 | |
| Novo Nordisk INC | $569.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $542.68 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $499.34 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $370.69 | 2019-2025 | |
| Amgen INC. | $232.49 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $201.65 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.77 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Abbott Laboratories | $125.17 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $104.05 | 2022-2025 | Rexulti, Abilify Maintena |
| Sanofi-Aventis U.S. LLC | $101.45 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $71.91 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $66.04 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $56.55 | 2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $47.69 | 2023-2025 | Cologuard Collection Kit |
| Abiomed | $45.46 | 2023 | Impella |
| Biogen, INC. | $44.61 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $42.59 | 2022-2025 | |
| Urovant Sciences INC | $39.48 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $38.92 | 2019-2023 | Pneumovax 23, Vaxneuvance, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $35.82 | 2020-2021 | |
| Dexcom, INC. | $35.75 | 2021-2023 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $34.96 | 2022 | |
| Edwards Lifesciences Corporation | $32.11 | 2025 | Sapien 3 Ultra Resilia |
| Bausch Health US, LLC | $31.36 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.04 | 2021-2022 | |
| Medtronic, INC. | $28.49 | 2021-2025 | Interstim |
| Allergan, INC. | $28.04 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $26.01 | 2020 | |
| Ibsa Pharma INC. | $23.12 | 2025 | Licart, Flector, Tirosint |
| Genentech USA, INC. | $19.32 | 2020 | |
| Lundbeck LLC | $16.75 | 2025 | Rexulti |
| Ethicon US, LLC | $15.88 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.52 | 2021 | |
| Esperion Therapeutics, INC. | $15.21 | 2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $14.73 | 2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $13.25 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.